A “narrow” patient population helped Eisai Co., Ltd. and Biogen, Inc.’s Alzheimer’s drug lecanemab avoid contraindications, a boxed warning and a risk-evaluation and mitigation strategy, Eisai said.
Eisai and Biogen’s amyloid-targeting antibody, which will be marketed as Leqembi, became the second drug of its type to gain...






